Head-to-head · WeighScore
Fella Health vs Remedy Meds
The verdict
Fella Health takes it — 64/100 to 51.8/100.
Fella Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fella Health is a medication weight loss program built specifically for men, offering compounded GLP-1 treatments (semaglutide and tirzepatide) plus free 1:1 health coaching, board-certified clinician care, and a 6-month money-back guarantee.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Fella Health | Remedy Meds |
|---|---|---|
| WeighScore | 64/100 | 51.8/100 |
| Grade | C | C |
| Scorecard rank | #267 | #526 |
| Semaglutide | $299/mo (compounded) | $299/mo (starting dose, compounded) |
| Tirzepatide | $449/mo (compounded) | $399/mo (starting dose, compounded) |
| Coverage | 20 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #267 · C
Strengths
- Specialized vertical — program designed for men, particularly 'bigger guys'
- Free 1:1 health coaching included with the membership
- 6-month money-back guarantee if the program doesn't work
- Flat monthly price stays the same as your dose escalates
- Both compounded semaglutide and tirzepatide available
Where it loses points
- Limited to men's health vertical — not available to women
- Available in only 20 published states (not nationwide)
- Exact GLP-1 monthly cost not published on the public site — only an 'under $10/day' starting figure
- Pricing transparency below industry standard for compounded GLP-1 telehealth
Graded #526 · C
FDAWarning letter issued to Remedy Meds in September 2025. See the FDA warning-letter database.
Strengths
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
Where it loses points
- Limited public information on program details
- FDA issued Remedy Meds a warning letter in September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 544 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.